TDM 812Alternative Names: TDM812
Latest Information Update: 20 May 2016
At a glance
- Originator 3-D Matrix
- Developer 3-D Matrix; National Cancer Center (Tokyo); National Cancer Research Institute
- Class Antineoplastics; Nucleic acids, nucleotides, and nucleosides; Peptides; Small interfering RNA
- Mechanism of Action RNA interference; Small interfering RNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer